AbbVie Inc. (ABBV), a pharmaceutical major, on Friday announced in its fourth-quarter earnings report that it has initiated its annual earnings outlook.
Excluding items, for the full year, the drug maker expects earnings per share of $11.05 to $11.25.
This guidance includes a $0.32 per share impact related to the proposed ImmunoGen and Cerevel Therapeutics acquisitions, which are anticipated to close in the middle of 2024.
On average, 27 analysts polled by Thomson Reuters forecast the firm to earn $11.24 per share, for the year. Analysts' estimates typically exclude special items.
For the full-year 2023, the company recorded adjusted income per share of $11.11.
In addition, AbbVie has reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.